Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™
02 nov. 2020 08h00 HE
|
Assembly Biosciences, Inc.
- Four posters, including two late breaking, will include new clinical and preclinical data on Assembly Bio’s hepatitis B virus (HBV) core inhibitor portfolio SOUTH SAN FRANCISCO, Calif., Nov. 02,...
Assembly Biosciences Appoints Gina Consylman to Board of Directors
20 oct. 2020 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award
15 oct. 2020 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Announces October Conference Participation
05 oct. 2020 07h30 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 oct. 2020 16h30 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 sept. 2020 16h30 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
28 août 2020 06h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 août 2020 16h30 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
05 août 2020 16h05 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
20 juil. 2020 06h30 HE
|
Assembly Biosciences, Inc.; BeiGene, Ltd.
-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million upfront payment and is eligible to receive up...